Product Description
Sodium polystyrene sulfonate is used to treat high levels of potassium in the blood, also called hyperkalemia. (Sourced from: https://www.mayoclinic.org/drugs-supplements/sodium-polystyrene-sulfonate-oral-route-route-not-applicable/description/drg-20073487)
Mechanisms of Action: Potassium Reducer
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral, Intramuscular
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Australia | Austria | Bangladesh | Belgium | Brazil | Chile | Colombia | Dominican Republic | Egypt | France | Germany | Hong Kong | India | Ireland | Italy | Malaysia | Morocco | New Zealand | Pakistan | Taiwan | Tunisia | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/16/2026 |
News Article |
KBRA Assigns Preliminary Ratings to GS Mortgage-Backed Securities Trust 2026-NQM1 (GSMBS 2026-NQM1) |
|
01/16/2026 |
News Article |
Liberty All-Star® Growth Fund, Inc. December 2025 Monthly Update |
|
01/13/2026 |
News Article |
DeFi Development Corp. Adopts Solstice YieldVault to Power Onchain Treasury Yield Strategy |
|
01/12/2026 |
News Article |
Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference |